Equities Analysts Offer Predictions for TVTX FY2025 Earnings

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share (EPS) estimate for Travere Therapeutics to ($1.25), up from a prior estimate of ($1.32), indicating a positive outlook for the company.
• The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share, and FY2026 earnings are projected at $1.00 EPS.
• Travere Therapeutics' stock carries an average rating of "Moderate Buy" with a consensus target price of $32.21, supported by multiple buy ratings from analysts.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Stock analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Travere Therapeutics in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($1.25) for the year, up from their previous estimate of ($1.32). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Cantor Fitzgerald also issued estimates for Travere Therapeutics' FY2026 earnings at $1.00 EPS.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.14. The company had revenue of $94.84 million for the quarter, compared to the consensus estimate of $100.18 million. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%. The firm's revenue was up 111.5% compared to the same quarter last year. During the same period last year, the business posted ($0.65) earnings per share.

TVTX has been the subject of a number of other research reports. Scotiabank reiterated an "outperform" rating on shares of Travere Therapeutics in a research note on Thursday, August 7th. Citigroup reaffirmed a "buy" rating on shares of Travere Therapeutics in a report on Sunday. Wedbush boosted their price target on shares of Travere Therapeutics from $30.00 to $32.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Stifel Nicolaus boosted their price target on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a "hold" rating in a report on Friday, May 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Travere Therapeutics in a research report on Tuesday, July 1st. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Travere Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $32.21.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded up $0.31 during mid-day trading on Monday, hitting $18.36. The company had a trading volume of 284,836 shares, compared to its average volume of 1,640,722. The company has a debt-to-equity ratio of 9.50, a current ratio of 2.00 and a quick ratio of 1.98. The business's 50-day simple moving average is $15.59 and its 200-day simple moving average is $17.74. Travere Therapeutics has a 12 month low of $8.46 and a 12 month high of $25.29. The firm has a market cap of $1.64 billion, a P/E ratio of -9.01 and a beta of 0.74.

Institutional Trading of Travere Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TVTX. Armistice Capital LLC raised its stake in shares of Travere Therapeutics by 20.6% during the first quarter. Armistice Capital LLC now owns 8,872,000 shares of the company's stock valued at $158,986,000 after acquiring an additional 1,514,000 shares during the last quarter. Rock Springs Capital Management LP raised its stake in shares of Travere Therapeutics by 6.2% during the fourth quarter. Rock Springs Capital Management LP now owns 4,973,649 shares of the company's stock valued at $86,641,000 after acquiring an additional 289,173 shares during the last quarter. Driehaus Capital Management LLC raised its stake in shares of Travere Therapeutics by 24.8% during the first quarter. Driehaus Capital Management LLC now owns 2,767,693 shares of the company's stock valued at $49,597,000 after acquiring an additional 549,718 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Travere Therapeutics by 479.9% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,184,898 shares of the company's stock valued at $39,153,000 after acquiring an additional 1,808,098 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Travere Therapeutics by 36.7% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company's stock valued at $37,875,000 after acquiring an additional 583,836 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.